Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Dumble

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Plos One|July 1, 2014
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorMelissa Dumble, Ming-Chih Crouthamel, Shu-Yun Zhang, et al.
Molecular Cancer Therapeutics|October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancerYixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
Journal of Medicinal Chemistry|May 5, 2018
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative BacteriaAleksey I Gerasyuto, Michael A Arnold, Jiashi Wang, et al.
Molecular Cancer Therapeutics|October 15, 2009
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersPeter Sabbatini, Susan Korenchuk, Jason L Rowand, et al.
Molecular Cancer Therapeutics|July 28, 2021
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding AgentFinith Jernigan, Arthur Branstrom, John D Baird, et al.
Journal of Medicinal Chemistry|February 24, 2011
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitorsJesús R Medina, Christopher J Becker, Charles W Blackledge, et al.
Journal of Medicinal Chemistry|April 22, 2026
Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven CancersLi Zheng, Eugene Park, Jason Lenihan, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Plos One|July 1, 2014
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorMelissa Dumble, Ming-Chih Crouthamel, Shu-Yun Zhang, et al.
Molecular Cancer Therapeutics|October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancerYixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
Journal of Medicinal Chemistry|May 5, 2018
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative BacteriaAleksey I Gerasyuto, Michael A Arnold, Jiashi Wang, et al.
Molecular Cancer Therapeutics|October 15, 2009
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersPeter Sabbatini, Susan Korenchuk, Jason L Rowand, et al.
Molecular Cancer Therapeutics|July 28, 2021
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding AgentFinith Jernigan, Arthur Branstrom, John D Baird, et al.
Journal of Medicinal Chemistry|February 24, 2011
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitorsJesús R Medina, Christopher J Becker, Charles W Blackledge, et al.
Journal of Medicinal Chemistry|April 22, 2026
Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven CancersLi Zheng, Eugene Park, Jason Lenihan, et al.
Pageof 2